Grunenthal
Grünenthal receives FDA Breakthrough Therapy Designation for knee osteoarthritis drug
May 23, 2023Medical Communications Breakthrough Therapy Designation, FDA, Grunenthal, Musculo-skeletal disorder, osteoarthritis
German pharmaceutical company Grünenthal has announced that the US Food and Drug Administration (FDA) has awarded it Breakthrough Therapy Designation …
Grünenthal buys European rights to AstraZeneca’s Crestor for a potential $350m
December 1, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, Crestor, Grunenthal
Grünenthal has picked up AstraZeneca’s statin therapy Crestor (rosuvastatin), currently approved in dyslipidaemia and hypercholesterolaemia treatment, in a deal worth …
Mundipharma signs Chinese licensing and distribution agreement with Grünenthal
January 16, 2018Manufacturing and Production China, Grunenthal, Mundipharma, Tramal, pharma
US-based firm Mundipharma is set to take over commercialisation and distribution duties for the analgesic Tramal (tramadol) in China on …
Five major pharma firms break ABPI code of conduct, according to watchdog
December 15, 2016Medical Communications, Sales and Marketing ABPI, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Grunenthal, Janssen
Eli Lilly, Boehgringer Ingelheim, AstraZeneca UK, Grunenthal and Janssen-Cilag have been “named and shamed” by the Prescription Medicines Code of …
AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America
June 2, 2016Business Services, Manufacturing and Production, Sales and Marketing AstraZeneca, Grunenthal, Licencing, Zurampic, gout, sales
UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million …
Grünenthal and Vifor breach Code
July 20, 2012Sales and Marketing ABPI, Grunenthal, PMCPA, Vifor, code, tapentadol
Grünenthal and Vifor Pharma UK have been named and shamed for serious infringements of the ABPI Code of Practice. Adverts …
Grunenthal in talks to sell pain drug portfolio
May 19, 2011Sales and Marketing Grunenthal, Stada, chronic pain, pain therapeutics
Grunenthal is negotiating a 360 million euro deal to sell Central and Eastern European rights to some of its pain …
Jango to manage Grünenthal pain awards
February 3, 2011Medical Communications Grunenthal, Jango, awards, disease awareness campaigns
Jango Communications has been appointed by Grünenthal to manage the Pain Awards Programme they are sponsoring this year. German-based Grünenthal, …
Novo rebuked after diabetes promotion breaches Code
December 16, 2010Medical Communications ABPI, ABPI Code of Practice, Grunenthal, Napp Pharmaceuticals, Novo Nordisk, PMCPA, diabetes, diabetes drug marketing, lilly
Novo Nordisk been ‘named and shamed’ in health trade journal advertisements this week for breaching the ABPI Code of Practice. …
Grünenthal breaches Code with off-label promotion
September 28, 2010Medical Communications Code of Practice, Grunenthal, PMCPA, Versatis
Grünenthal has been severely criticised in two rulings by UK pharma’s self-regulatory body the PMCPA for promoting off-label use of …
Grunenthal’s new pain treatment approved in US
November 27, 2008Sales and Marketing Grunenthal
The first new oral centrally acting analgesic in more than 25 years has been approved in the US.Tapentadol was developed …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
